+6.2%
ABNB vs MRNA
-67.9%
+74.0%
-60.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.5% | +5.4% | -3.9% | +1.1% |
| 7D | -6.5% | -1.1% | -5.4% | -6.4% |
| 30D | -5.5% | +126.1% | -131.6% | -17.7% |
| 3M | +30.0% | +190.0% | -160.0% | +7.5% |
| 6M | +27.6% | +157.2% | -129.6% | +7.2% |
| YTD | +25.4% | +388.2% | -362.8% | -7.2% |
| 1Y | +38.3% | +467.0% | -428.7% | -1.5% |
| 3Y | +15.5% | +36.1% | -20.6% | -0.3% |
| All | +6.2% | -67.9% | +74.0% | -7.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling